BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Seimetz D, Heller K, Richter J. Approval of First CAR-Ts: Have we Solved all Hurdles for ATMPs? Cell Med. 2019;11:2155179018822781. [PMID: 32634192 DOI: 10.1177/2155179018822781] [Cited by in Crossref: 39] [Cited by in F6Publishing: 27] [Article Influence: 19.5] [Reference Citation Analysis]
Number Citing Articles
1 Khan M, Maker AV, Jain S. The Evolution of Cancer Immunotherapy. Vaccines (Basel) 2021;9:614. [PMID: 34200997 DOI: 10.3390/vaccines9060614] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Cortés-Hernández A, Alvarez-Salazar EK, Soldevila G. Chimeric Antigen Receptor (CAR) T Cell Therapy for Cancer. Challenges and Opportunities: An Overview. Methods Mol Biol 2021;2174:219-44. [PMID: 32813253 DOI: 10.1007/978-1-0716-0759-6_14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Wang LL, Janes ME, Kumbhojkar N, Kapate N, Clegg JR, Prakash S, Heavey MK, Zhao Z, Anselmo AC, Mitragotri S. Cell therapies in the clinic. Bioeng Transl Med 2021;6:e10214. [PMID: 34027097 DOI: 10.1002/btm2.10214] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
4 Alhawaj AF. Stem cell-based therapy for hirschsprung disease, do we have the guts to treat? Gene Ther 2021. [PMID: 34121091 DOI: 10.1038/s41434-021-00268-4] [Reference Citation Analysis]
5 Zhou Y, Maldini CR, Jadlowsky J, Riley JL. Challenges and Opportunities of Using Adoptive T-Cell Therapy as Part of an HIV Cure Strategy. J Infect Dis 2021;223:38-45. [PMID: 33586770 DOI: 10.1093/infdis/jiaa223] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
6 El-Khazragy N, Ghozy S, Emad P, Mourad M, Razza D, Farouk YK, Mohamed NA, Ahmed MK, Youssef T, Bahnasawy YM, Elmasery S. Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies. Immunotherapy 2020;12:1341-57. [PMID: 33148070 DOI: 10.2217/imt-2020-0181] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Wang X, Peticone C, Kotsopoulou E, Göttgens B, Calero-Nieto FJ. Single-cell transcriptome analysis of CAR T-cell products reveals subpopulations, stimulation, and exhaustion signatures. Oncoimmunology 2021;10:1866287. [PMID: 33489472 DOI: 10.1080/2162402X.2020.1866287] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
8 Krabbe T, Marek J, Groll T, Steiger K, Schmid RM, Krackhardt AM, Altomonte J. Adoptive T Cell Therapy Is Complemented by Oncolytic Virotherapy with Fusogenic VSV-NDV in Combination Treatment of Murine Melanoma. Cancers (Basel) 2021;13:1044. [PMID: 33801359 DOI: 10.3390/cancers13051044] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Theoharis S. Current State of the Art of Allogeneic CAR Approaches - Pile 'Em High and Sell 'Em Cheap. J Pharm Sci 2021;110:1909-14. [PMID: 33577827 DOI: 10.1016/j.xphs.2021.02.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
10 Krishna D, Rittié L, Tran H, Zheng X, Chen-Rogers CE, McGillivray A, Clay T, Ketkar A, Tarnowski J. Short Time to Market and Forward Planning Will Enable Cell Therapies to Deliver R&D Pipeline Value. Hum Gene Ther 2021;32:433-45. [PMID: 33023309 DOI: 10.1089/hum.2020.212] [Reference Citation Analysis]
11 Islam R, Pupovac A, Evtimov V, Boyd N, Shu R, Boyd R, Trounson A. Enhancing a Natural Killer: Modification of NK Cells for Cancer Immunotherapy. Cells 2021;10:1058. [PMID: 33946954 DOI: 10.3390/cells10051058] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Horgan D, Metspalu A, Ouillade MC, Athanasiou D, Pasi J, Adjali O, Harrison P, Hermans C, Codacci-Pisanelli G, Koeva J, Szucs T, Cursaru V, Belina I, Bernini C, Zhuang S, McMahon S, Toncheva D, Thum T. Propelling Healthcare with Advanced Therapy Medicinal Products: A Policy Discussion. Biomed Hub 2020;5:130-52. [PMID: 33987187 DOI: 10.1159/000511678] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Zhang Y, Williams Iii RO, Tucker HO. Formulation strategies in immunotherapeutic pharmaceutical products. World J Clin Oncol 2020;11:275-82. [PMID: 32728530 DOI: 10.5306/wjco.v11.i5.275] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Umemura M, Morrison M. Comparative lessons in regenerative medicine readiness: learning from the UK and Japanese experience. Regen Med 2021;16:269-82. [PMID: 33781099 DOI: 10.2217/rme-2020-0136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Cavero I, Seimetz D, Koziel D, Zimmermann WH, Holzgrefe HH. 19th Annual Meeting of the Safety Pharmacology Society: regulatory and safety perspectives for advanced therapy medicinal products (cellular and gene therapy products). Expert Opin Drug Saf. 2020;19:553-558. [PMID: 32163309 DOI: 10.1080/14740338.2020.1741546] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Wang L, Bhardwaj R, Mostowski H, Patrone PN, Kearsley AJ, Watson J, Lim L, Pichaandi J, Ornatsky O, Majonis D, Bauer SR, Degheidy HA. Establishing CD19 B-cell reference control materials for comparable and quantitative cytometric expression analysis. PLoS One 2021;16:e0248118. [PMID: 33740004 DOI: 10.1371/journal.pone.0248118] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Sharma G, Sharma AR, Bhattacharya M, Lee SS, Chakraborty C. CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases. Mol Ther 2021;29:571-86. [PMID: 33238136 DOI: 10.1016/j.ymthe.2020.09.028] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
18 Rotolo A, Chabannon C, Gramignoli R. Identification of hurdles in the development of cell-based therapies. Cytotherapy 2020;22:53-6. [PMID: 32081172 DOI: 10.1016/j.jcyt.2019.12.009] [Reference Citation Analysis]
19 Verdugo-Avello FJ, Wychowaniec JK, Jimenez M, Jimenez S, Gutierrez S. Current concepts for tissue transplant services for developing countries. Cell Tissue Bank 2021. [PMID: 33398493 DOI: 10.1007/s10561-020-09891-8] [Reference Citation Analysis]
20 Li LZ, Zhang Z, Bhoj VG. Conventional T cell therapies pave the way for novel Treg therapeutics. Cell Immunol 2021;359:104234. [PMID: 33153708 DOI: 10.1016/j.cellimm.2020.104234] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Yip V, Figueroa I, Latifi B, Masih S, Ng C, Leipold D, Kamath A, Shen BQ. Anti-Lymphocyte Antigen 6 Complex, Locus E-Seco-Cyclopropabenzindol-4-One-Dimer Antibody-Drug Conjugate That Forms Adduct with α1-Microglobulin Demonstrates Slower Systemic Antibody Clearance and Reduced Tumor Distribution in Animals. Drug Metab Dispos 2020;48:1247-56. [PMID: 33020064 DOI: 10.1124/dmd.120.000145] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
22 Dasyam N, George P, Weinkove R. Chimeric antigen receptor T-cell therapies: Optimising the dose. Br J Clin Pharmacol 2020;86:1678-89. [PMID: 32175617 DOI: 10.1111/bcp.14281] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
23 Brown AJ, Snapkov I, Akbar R, Pavlović M, Miho E, Sandve GK, Greiff V. Augmenting adaptive immunity: progress and challenges in the quantitative engineering and analysis of adaptive immune receptor repertoires. Mol Syst Des Eng 2019;4:701-36. [DOI: 10.1039/c9me00071b] [Cited by in Crossref: 26] [Article Influence: 13.0] [Reference Citation Analysis]
24 Schmidts A, Marsh LC, Srivastava AA, Bouffard AA, Boroughs AC, Scarfò I, Larson RC, Bedoya F, Choi BD, Frigault MJ, Bailey SR, Leick MB, Vatsa S, Kann MC, Prew MS, Kleinstiver BP, Joung JK, Maus MV. Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources. J Immunother Cancer 2020;8:e000990. [PMID: 32900862 DOI: 10.1136/jitc-2020-000990] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
25 Li A, James D, Lim R. The Gibco CTS Rotea system story-a case study of industry-academia collaboration. Gene Ther 2021. [PMID: 34108630 DOI: 10.1038/s41434-021-00266-6] [Reference Citation Analysis]
26 O'sullivan GM, Velickovic ZM, Keir MW, Macpherson JL, Rasko JE. Cell and gene therapy manufacturing capabilities in Australia and New Zealand. Cytotherapy 2019;21:1258-73. [DOI: 10.1016/j.jcyt.2019.10.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]